Leukemia CLL Panel by Flow Cytometry
What it is
The Leukemia CLL Panel by Flow Cytometry is a specialized diagnostic test that analyzes blood or bone marrow samples to detect and characterize Chronic Lymphocytic Leukemia (CLL). Using flow cytometry technology, this test evaluates the presence of abnormal lymphocytes by studying their surface markers (immunophenotyping). It helps confirm the diagnosis of CLL and distinguish it from other types of leukemia or lymphoproliferative disorders.
Uses
This test is primarily used to diagnose CLL, classify lymphoid malignancies, and monitor disease progression. It also helps in distinguishing CLL from other B-cell disorders such as mantle cell lymphoma or hairy cell leukemia. Flow cytometry results are often combined with other clinical findings, genetic studies, and laboratory results to guide treatment decisions.
Symptoms That May Lead to the Test
Doctors may recommend this panel if you experience persistent fatigue, unexplained weight loss, night sweats, frequent infections, swollen lymph nodes, enlarged spleen, or abnormal blood counts (especially elevated lymphocytes). It may also be ordered after routine blood work reveals suspicious findings suggestive of leukemia.
Abnormal Results
CLL Immunophenotype: Typically shows abnormal B-lymphocytes expressing markers such as CD5, CD19, CD20 (dim), and CD23, with restricted light chain expression (kappa or lambda). This confirms the diagnosis of CLL.
Other Abnormal Patterns: May indicate alternative lymphoproliferative disorders such as mantle cell lymphoma, follicular lymphoma, or hairy cell leukemia, requiring further evaluation.
Normal Result: Suggests no abnormal lymphocyte population detected, making CLL unlikely.
Risks
The test requires either a blood sample or bone marrow aspirate. Risks include mild pain, bruising, or dizziness at the collection site. Bone marrow aspiration may cause temporary soreness or discomfort. Serious complications are rare when performed under medical supervision.



Reviews
There are no reviews yet.